Literature DB >> 26477685

Trialing and Maintenance Dosing Using a Low-Dose Intrathecal Opioid Method for Chronic Nonmalignant Pain: A Prospective 36-Month Study.

Jay S Grider1, Mark A Etscheidt1, Michael E Harned1, Jason Lee1, Ben Smith1, Christina Lamar1, Anjum Bux2.   

Abstract

OBJECTIVE: To evaluate low-dose intrathecal opioid trialing and maintenance with regard to analgesia and psychometric functional capacity.
MATERIALS AND METHODS: Prospective cohort of subjects offered, trialed and maintained using low-dose opioid therapy via an intrathecal drug delivery system. Analgesia, measured by visual analog scale and the Global Pain Scale, and function, measured by Multidimensional Pain Inventory and Global Pain Scale, are evaluated. Population analysis by age, gender, oral opioid dose, diagnosis, and pain type is reported.
RESULTS: Fifty-eight subjects enrolled in the 36-month evaluation period with mean opioid intrathecal opioid dose less than 350 μg per day of morphine equivalent utilized. Primary nociceptive pain type were associated with lower intrathecal opioid doses and improved visual analog scale pain rating and improved pain severity and interference on the Multidimensional Pain Inventory.
CONCLUSIONS: This study adds to the growing body of literature suggesting that low-dose intrathecal analgesia without oral opioid supplementation can be efficacious. It appears that this approach may achieve analgesia with lower doses in those with primary nociceptive pain type.
© 2015 International Neuromodulation Society.

Entities:  

Keywords:  Chronic benign pain; intrathecal drug delivery; intrathecal opioids; oral opioid therapy

Mesh:

Substances:

Year:  2015        PMID: 26477685     DOI: 10.1111/ner.12352

Source DB:  PubMed          Journal:  Neuromodulation        ISSN: 1094-7159


  7 in total

Review 1.  Managing Chronic Non-Malignant Pain in the Elderly: Intrathecal Therapy.

Authors:  Barbara Kleinmann; Tilman Wolter
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

Review 2.  Best Practices for Minimally Invasive Lumbar Spinal Stenosis Treatment 2.0 (MIST): Consensus Guidance from the American Society of Pain and Neuroscience (ASPN).

Authors:  Timothy R Deer; Jay S Grider; Jason E Pope; Tim J Lamer; Sayed E Wahezi; Jonathan M Hagedorn; Steven Falowski; Reda Tolba; Jay M Shah; Natalie Strand; Alex Escobar; Mark Malinowski; Anjum Bux; Navdeep Jassal; Jennifer Hah; Jacqueline Weisbein; Nestor D Tomycz; Jessica Jameson; Erika A Petersen; Dawood Sayed
Journal:  J Pain Res       Date:  2022-05-05       Impact factor: 2.832

Review 3.  Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options.

Authors:  Timothy R Deer; Jason E Pope; Michael C Hanes; Gladstone C McDowell
Journal:  Pain Med       Date:  2019-04-01       Impact factor: 3.750

4.  Systemic Opioid Reduction and Discontinuation Following Implantation of Intrathecal Drug-Delivery Systems for Chronic Pain: A Retrospective Cohort Analysis.

Authors:  John A Hatheway; Megha Bansal; Christine I Nichols-Ricker
Journal:  Neuromodulation       Date:  2019-10-11

Review 5.  A Call to Action Toward Optimizing the Electrical Dose Received by Neural Targets in Spinal Cord Stimulation Therapy for Neuropathic Pain.

Authors:  Krishnan Chakravarthy; Rajiv Reddy; Adnan Al-Kaisy; Thomas Yearwood; Jay Grider
Journal:  J Pain Res       Date:  2021-09-07       Impact factor: 2.832

Review 6.  Multidisciplinary Firms and the Treatment of Chronic Pain: A Case Study of Low Back Pain.

Authors:  Julie G Pilitsis; Olga Khazen; Nikolai G Wenzel
Journal:  Front Pain Res (Lausanne)       Date:  2021-11-10

7.  Targeted Drug Delivery for Chronic Nonmalignant Pain: Longitudinal Data From the Product Surveillance Registry.

Authors:  David M Schultz; Alaa Abd-Elsayed; Aaron Calodney; Katherine Stromberg; Todd Weaver; Robert J Spencer
Journal:  Neuromodulation       Date:  2021-01-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.